[P25-10] P25-10: Oncologic drugs (2)

[P25-10-5] Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in advanced non-small cell lung cancer (NSCLC) NCT02058433

Salvatore Joseph Salamone¹, Jie Zhang², Huiwei Qi³, Huijuan Ni⁴, Yunying Li⁵, Jodi Courtney⁶, Caicun Zhou⁷ (1.Saladax Biomedical, Inc., 2.Shanghai Pulmonary Hosptial, 3.Shanghai Pulmonary Hosptial, 4.Shanghai Pulmonary Hospital, 5.Saladax Biomedical, Inc, 6.Saladax Biomedical, Inc, 7.Shanghai Pulmonary Hosptial)

Keywords:paclitaxel, non-small cell lung cancer, Pharmacokinetically guided dosing, randomized trial